Hi. I'm Dr Richard Isaacson, director of the Alzheimer's Prevention Clinic at Weill Cornell Medicine and NewYork-Presbyterian. I'm excited to talk today about a new article in Alzheimer's and Dementia, which is the journal of the Alzheimer's Association.
The article is titled, "The clinical practice of risk reduction for Alzheimer's disease: a precision medicine approach."[1] This article underscores what clinicians can do today, in an evidence-based and structured way, to help patients reduce their risk tomorrow. This is a paper that describes the clinical approach at the Alzheimer's Prevention Clinic at Weill Cornell and at the Alzheimer's Prevention Clinic & Research Center of Puerto Rico in San Juan.
This article goes through the ABCs of Alzheimer prevention management, which describe a way for clinicians to evaluate a patient, assess a patient's risk, and then give a patient a personalized plan for risk reduction. The A is for anthropometrics, the B is for blood-based biomarkers, and the C is for cognitive performance. The key here is for any clinician to try to give someone an evidence-based approach. There is no magic pill or magic potion to prevent or cure Alzheimer disease, and until a blockbuster drug comes, clinicians are struggling to figure out what can be done today.
Trending Clinical Topic: Periodontal Disease
Alzheimer Disease
Alcohol Use Disorder and the Risk of Neurodegenerative Diseases
COMMENTARY
A Precision Medicine Approach to Alzheimer Risk Reduction
Richard S. Isaacson, MD
DisclosuresDecember 03, 2018
Hi. I'm Dr Richard Isaacson, director of the Alzheimer's Prevention Clinic at Weill Cornell Medicine and NewYork-Presbyterian. I'm excited to talk today about a new article in Alzheimer's and Dementia, which is the journal of the Alzheimer's Association.
The article is titled, "The clinical practice of risk reduction for Alzheimer's disease: a precision medicine approach."[1] This article underscores what clinicians can do today, in an evidence-based and structured way, to help patients reduce their risk tomorrow. This is a paper that describes the clinical approach at the Alzheimer's Prevention Clinic at Weill Cornell and at the Alzheimer's Prevention Clinic & Research Center of Puerto Rico in San Juan.
This article goes through the ABCs of Alzheimer prevention management, which describe a way for clinicians to evaluate a patient, assess a patient's risk, and then give a patient a personalized plan for risk reduction. The A is for anthropometrics, the B is for blood-based biomarkers, and the C is for cognitive performance. The key here is for any clinician to try to give someone an evidence-based approach. There is no magic pill or magic potion to prevent or cure Alzheimer disease, and until a blockbuster drug comes, clinicians are struggling to figure out what can be done today.
Medscape Neurology © 2018 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Richard S. Isaacson. A Precision Medicine Approach to Alzheimer Risk Reduction - Medscape - Dec 03, 2018.
Tables
References
Authors and Disclosures
Authors and Disclosures
Author(s)
Richard S. Isaacson, MD
Associate Professor, Department of Neurology, Weill Cornell Medicine, New York, New York
Disclosure: Richard S. Isaacson, has disclosed the following relevant financial relationships:
Serve(d) as a scientific advisor for: Accera, Inc